Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 2
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM, Hirsh NH, Chandler BC, Michmerhuizen AR, Ritter CL, Androsiglio MP, Wilder-Romans K, Liu M, Gersch CL, Larios JM, Pierce LJ, Rae JM, Speers CW. Pesch AM, et al. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580. doi: 10.1158/1078-0432.CCR-20-2269. Epub 2020 Sep 23. Clin Cancer Res. 2020. PMID: 32967938 Free PMC article.
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Michmerhuizen AR, et al. Among authors: pesch am. NPJ Breast Cancer. 2022 Mar 10;8(1):31. doi: 10.1038/s41523-022-00397-y. NPJ Breast Cancer. 2022. PMID: 35273179 Free PMC article.
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Michmerhuizen AR, et al. Among authors: pesch am. NPJ Breast Cancer. 2022 Apr 20;8(1):54. doi: 10.1038/s41523-022-00418-w. NPJ Breast Cancer. 2022. PMID: 35444242 Free PMC article. No abstract available.
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
Chandler BC, Moubadder L, Ritter CL, Liu M, Cameron M, Wilder-Romans K, Zhang A, Pesch AM, Michmerhuizen AR, Hirsh N, Androsiglio M, Ward T, Olsen E, Niknafs YS, Merajver S, Thomas DG, Brown PH, Lawrence TS, Nyati S, Pierce LJ, Chinnaiyan A, Speers C. Chandler BC, et al. Among authors: pesch am. J Clin Invest. 2020 Feb 3;130(2):958-973. doi: 10.1172/JCI130435. J Clin Invest. 2020. PMID: 31961339 Free PMC article.
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, Ritter CL, Liu M, Nyati S, Pierce LJ, Jagsi R, Speers C. Michmerhuizen AR, et al. Among authors: pesch am. Mol Cancer Ther. 2019 Nov;18(11):2063-2073. doi: 10.1158/1535-7163.MCT-19-0520. Epub 2019 Aug 14. Mol Cancer Ther. 2019. PMID: 31413177 Free PMC article.
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL. Dempsey JM, et al. Among authors: pesch am. Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020. Pharmacogenomics. 2019. PMID: 31190621 Free PMC article. Clinical Trial.
12 results